Wells Fargo & Company reiterated their hold rating on shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) in a research note published on Tuesday morning.

Several other research firms have also commented on TEVA. Mizuho lowered shares of Teva Pharmaceutical Industries Limited from a buy rating to a neutral rating and lowered their price objective for the company from $64.00 to $45.00 in a research report on Monday, October 24th. Zacks Investment Research upgraded shares of Teva Pharmaceutical Industries Limited from a sell rating to a hold rating in a research report on Wednesday, October 19th. Credit Suisse Group upgraded shares of Teva Pharmaceutical Industries Limited from a neutral rating to an outperform rating and lowered their price objective for the company from $59.00 to $52.00 in a research report on Monday, October 31st. They noted that the move was a valuation call. RBC Capital Markets set a $58.00 price objective on shares of Teva Pharmaceutical Industries Limited and gave the company a buy rating in a research report on Monday, November 14th. Finally, Royal Bank Of Canada lowered their price objective on shares of Teva Pharmaceutical Industries Limited from $71.00 to $58.00 and set an outperform rating for the company in a research report on Monday, November 14th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and sixteen have given a buy rating to the company’s stock. The stock presently has an average rating of Hold and an average target price of $50.42.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) opened at 35.81 on Tuesday. Teva Pharmaceutical Industries Limited has a 52-week low of $31.90 and a 52-week high of $59.35. The stock has a market cap of $36.35 billion, a PE ratio of 511.57 and a beta of 0.58. The firm has a 50 day moving average of $34.45 and a 200-day moving average of $42.38.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last released its quarterly earnings data on Monday, February 13th. The company reported $1.38 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.36 by $0.02. Teva Pharmaceutical Industries Limited had a net margin of 1.50% and a return on equity of 17.46%. The business earned $6.25 billion during the quarter, compared to analyst estimates of $6.26 billion. During the same quarter last year, the business earned $1.32 earnings per share. Teva Pharmaceutical Industries Limited’s quarterly revenue was up 33.0% compared to the same quarter last year. Equities analysts anticipate that Teva Pharmaceutical Industries Limited will post $4.75 earnings per share for the current fiscal year.

This piece of content was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another website, it was illegally stolen and republished in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be accessed at http://www.dailypolitical.com/2017/02/17/teva-pharmaceutical-industries-limiteds-teva-hold-rating-reaffirmed-at-wells-fargo-company.html.

The business also recently declared a quarterly dividend, which will be paid on Monday, March 20th. Investors of record on Thursday, March 2nd will be paid a $0.34 dividend. This represents a $1.36 annualized dividend and a yield of 3.80%. The ex-dividend date is Tuesday, February 28th. Teva Pharmaceutical Industries Limited’s dividend payout ratio is presently 1,657.38%.

A number of hedge funds and other institutional investors have recently bought and sold shares of TEVA. Sharkey Howes & Javer increased its position in Teva Pharmaceutical Industries Limited by 21.7% in the second quarter. Sharkey Howes & Javer now owns 2,008 shares of the company’s stock worth $101,000 after buying an additional 358 shares during the period. Hudock Capital Group LLC increased its position in Teva Pharmaceutical Industries Limited by 37.6% in the second quarter. Hudock Capital Group LLC now owns 2,064 shares of the company’s stock worth $103,000 after buying an additional 564 shares during the period. Washington Trust Bank increased its position in Teva Pharmaceutical Industries Limited by 2.7% in the third quarter. Washington Trust Bank now owns 2,232 shares of the company’s stock worth $103,000 after buying an additional 58 shares during the period. Kistler Tiffany Companies LLC increased its position in Teva Pharmaceutical Industries Limited by 14.1% in the third quarter. Kistler Tiffany Companies LLC now owns 2,437 shares of the company’s stock worth $112,000 after buying an additional 302 shares during the period. Finally, JFS Wealth Advisors LLC increased its position in Teva Pharmaceutical Industries Limited by 139.0% in the third quarter. JFS Wealth Advisors LLC now owns 2,495 shares of the company’s stock worth $115,000 after buying an additional 1,451 shares during the period. 55.03% of the stock is currently owned by institutional investors.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules.

5 Day Chart for NYSE:TEVA

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.